## Anders Lund

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12002772/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ketamine: use in psychiatry, its pharmacology and treatment following intoxication. Minerva Psychiatry, 2021, 62, .	0.3	Ο
2	Effect of D-Cycloserine on the Effect of Concentrated Exposure and Response Prevention in Difficult-to-Treat Obsessive-Compulsive Disorder. JAMA Network Open, 2020, 3, e2013249.	5.9	16
3	Blueâ€blocking glasses as additive treatment for mania: Effects on actigraphyâ€derived sleep parameters. Journal of Sleep Research, 2020, 29, e12984.	3.2	22
4	Diabetes is associated with decreased migraine risk: A nationwide cohort study. Cephalalgia, 2018, 38, 1759-1764.	3.9	14
5	Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 161-175.	2.2	67
6	Blueâ€blocking glasses as additive treatment for mania: a randomized placeboâ€controlled trial. Bipolar Disorders, 2016, 18, 221-232.	1.9	102
7	Cognitive functioning and cortisol profiles in first episode major depression. Scandinavian Journal of Psychology, 2015, 56, 379-383.	1.5	21
8	Depression in Persons with Diabetes by Age and Antidiabetic Treatment: A Cross-Sectional Analysis with Data from the Hordaland Health Study. PLoS ONE, 2015, 10, e0127161.	2.5	23
9	Blocking blue light during mania – markedly increased regularity of sleep and rapid improvement of symptoms: a case report. Bipolar Disorders, 2014, 16, 894-898.	1.9	34
10	Lithium: A review of pharmacology, clinical uses, and toxicity. European Journal of Pharmacology, 2014, 740, 464-473.	3.5	147
11	Does Diabetes Have a Protective Effect on Migraine?. Epidemiology, 2013, 24, 129-134.	2.7	29
12	The relationship between residual symptoms of depression and emotional information processing. Nordic Journal of Psychiatry, 2013, 67, 233-239.	1.3	3
13	Cognitive functioning and cortisol suppression in recurrent major depression. PsyCh Journal, 2013, 2, 167-174.	1.1	8
14	Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences. BMC Medicine, 2012, 10, 148.	5.5	16
15	Testing the cognitive effort hypothesis of cognitive impairment in major depression. Nordic Journal of Psychiatry, 2011, 65, 74-80.	1.3	34
16	A pharmaco-epidemiological study of migraine and antidepressant medications: Complete one year data from the Norwegian population. Journal of Affective Disorders, 2011, 129, 198-204.	4.1	9
17	Comorbidity of Asthma With ADHD. Journal of Attention Disorders, 2011, 15, 564-571.	2.6	29
18	Are Migraine and Bipolar Disorders Comorbid Phenomena?. Journal of Clinical Psychopharmacology, 2011, 31, 734-739.	1.4	10

Anders Lund

#	Article	IF	CITATIONS
19	Prolonged Impairment in Inhibition and Semantic Fluency in a Follow-up Study of Recurrent Major Depression. Archives of Clinical Neuropsychology, 2011, 26, 677-686.	0.5	28
20	An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?. Journal of Chemical Biology, 2010, 3, 67-88.	2.2	20
21	Enduring cognitive dysfunction in unipolar major depression: A test–retest study using the Stroop paradigm. Scandinavian Journal of Psychology, 2009, 51, 304-8.	1.5	51
22	A Review of Modern Antidepressants Effects on Neurocognitive Function. Current Psychiatry Reviews, 2009, 5, 164-174.	0.9	52
23	Left hemisphere lateralisation of auditory hallucinations in schizophrenia: A dichotic listening study. Cognitive Neuropsychiatry, 2008, 13, 166-179.	1.3	52
24	A longitudinal analysis of neurocognitive function in unipolar depression. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 879-891.	1.3	75
25	Increased Parietal and Frontal Activation after Remission from Recurrent Major Depression: A Repeated fMRI Study. Cognitive Therapy and Research, 2007, 31, 147-160.	1.9	12
26	MR MORPHOMETRY ANALYSIS OF GREY MATTER VOLUME REDUCTION IN SCHIZOPHRENIA: ASSOCIATION WITH HALLUCINATIONS. International Journal of Neuroscience, 2006, 116, 9-23.	1.6	130
27	Validation of distinct amnesic and executive type memory deficit in a psychiatric sample based on retrieval performance. Scandinavian Journal of Psychology, 2005, 46, 201-208.	1.5	8
28	Executive function improvement upon remission of recurrent unipolar depression. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 373-380.	3.2	113
29	Frequency and characteristics of recurrent major depressed patients with unimpaired executive functions. World Journal of Biological Psychiatry, 2005, 6, 36-44.	2.6	19
30	Brain Activation Measured With fMRI During a Mental Arithmetic Task in Schizophrenia and Major Depression. American Journal of Psychiatry, 2004, 161, 286-293.	7.2	144
31	Impairment across executive functions in recurrent major depression. Nordic Journal of Psychiatry, 2004, 58, 41-47.	1.3	151
32	Attentional and executive dysfunctions in schizophrenia and depression: evidence from dichotic listening performance. Biological Psychiatry, 2003, 53, 609-616.	1.3	88
33	Long-lasting cognitive impairment in unipolar major depression: a 6-month follow-up study. Psychiatry Research, 2003, 118, 189-196.	3.3	77
34	Sensitivity and Specificity of Memory Dysfunction in Schizophrenia: A Comparison With Major Depression. Journal of Clinical and Experimental Neuropsychology, 2003, 25, 79-93.	1.3	96
35	Selective impairment in effortful information processing in major depression. Journal of the International Neuropsychological Society, 2003, 9, 954-959.	1.8	66
36	Honig's model of working memory and brain activation: an fMRI study. NeuroReport, 2001, 12, 4047-4054.	1.2	23

Anders Lund

#	Article	IF	CITATIONS
37	Venlafaxine Treatment Stimulates Blood Platelet Activity. Journal of Clinical Psychopharmacology, 2000, 20, 589-590.	1.4	5
38	Bergen Psychiatric Emergency Room: The patients' sociomedical characteristics, patterns of use, and management. Nordic Journal of Psychiatry, 1997, 51, 423-429.	1.3	1
39	Psychological and behavioural aspects of pain. , 1994, , 183-201.		1
40	Neurochemical similarities in depression and pain, with special emphasis on serotonin. Nordic Journal of Psychiatry, 1994, 48, 419-428.	1.3	2
41	Chronic, combined treatment with desipramine and mianserin: Enhanced 5-HT1A receptor function and altered 5-HT1A/5-HT2 receptor interaction in rats. Pharmacology Biochemistry and Behavior, 1993, 45, 777-783.	2.9	8
42	Intrathecal co-administration of substance P and NMDA augments nociceptive responses in the formalin test. Pain, 1992, 51, 195-198.	4.2	49
43	Potentiation of a behavioural response in mice by spinal coadministration of substance P and excitatory amino acid agonists. Neuroscience Letters, 1991, 133, 121-124.	2.1	62
44	The Behavioural Response to Intrathecal Serotonin is Changed by Acute but not by Repeated Treatment with Zimelidine or Metergoline. Basic and Clinical Pharmacology and Toxicology, 1991, 69, 361-364.	0.0	3
45	The role of descending noradrenergic systems in regulation of nociception: the effects of intrathecally administeredt α-adrenoceptor antagonists and clonidine. Pain, 1990, 43, 113-120.	4.2	35
46	The tail-flick test needs to be improved. Pain, 1990, 43, 391-392.	4.2	19
47	The apparent hyperalgesic effect of a serotonin antagonist in the tail flick test is mainly due to increased tail skin temperature. Pharmacology Biochemistry and Behavior, 1989, 32, 601-605.	2.9	23
48	An improved method for tail-flick testing with adjustment for tail-skin temperature. Journal of Neuroscience Methods, 1989, 26, 259-265.	2.5	93
49	The apparent antinociceptive effect of desipramine and zimelidine in the tail flick test in rats is mainly caused by changes in tail skin temperature. Pain, 1989, 38, 65-69.	4.2	29